NK Cell immunotherapy for high-risk neuroblastoma relapse after haploidentical HSCT

Autor: Peter Lang, Emmanuelle Rochette, Andrei Tchirkov, Catherine Paillard, Justyna Kanold, Etienne Merlin, F. Isfan, Pascale Halle, Antony Kelly, François Demeocq, Aurélien Marabelle
Rok vydání: 2011
Předmět:
Doublecortin Domain Proteins
Male
Oncology
Neoplasm
Residual
medicine.medical_treatment
Adrenal Gland Neoplasms
Neuroblastoma
Child
Remission Induction
Hematopoietic Stem Cell Transplantation
Hematology
Combined Modality Therapy
Dacarbazine
Killer Cells
Natural
surgical procedures
operative
Immunotherapy
Stem cell
Microtubule-Associated Proteins
medicine.drug
endocrine system
medicine.medical_specialty
Tyrosine 3-Monooxygenase
Bone Neoplasms
Refractory
Internal medicine
Biomarkers
Tumor
Temozolomide
medicine
Humans
Transplantation
Homologous
Antineoplastic Agents
Alkylating
Homeodomain Proteins
business.industry
Neuropeptides
Therapeutic effect
medicine.disease
Transplantation
Haplotypes
Pediatrics
Perinatology and Child Health
Immunology
Interleukin-2
Topotecan
Bone Marrow Neoplasms
business
Transcription Factors
Zdroj: Pediatric Blood & Cancer. 59:739-742
ISSN: 1545-5009
Popis: Little is known on strategies to prevent or to treat relapses occurring after haploidentical stem cell transplantation (haplo-HSCT) performed for the high-risk neuroblastoma (NB). We describe a 6-year-old male with refractory NB who relapsed 22 months after haplo-HSCT. A complete remission was obtained with a combination of immuno-chemotherapy based on donor NK cells transplants, IL2 infusions and temozolomide/topotecan. This case is an incentive to explore both the immediate therapeutic effect of haplo-graft provided via haplo-NK cells and the immunogenic platform that haplo-HSCT offers for future treatment. Our post-relapse strategy shows that chemo- and bio-treatment should be viewed as complementary therapeutic options. Pediatr Blood Cancer 2012;59:739–742. © 2011 Wiley Periodicals, Inc.
Databáze: OpenAIRE
Externí odkaz: